NCT03734029 2025-10-06Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]Daiichi SankyoPhase 3 Active not recruiting557 enrolled 22 charts 1 FDA
NCT02819518 2024-11-27KEYNOTE-355Merck Sharp & Dohme LLCPhase 3 Completed882 enrolled 41 charts 2 FDA